Recombinant EGFR (Zalutumumab Biosimilar) 抗体
适用: 人
ELISA, FACS, WB
宿主: Human
Monoclonal
2F8
unconjugated
Recombinant Antibody
-
- 抗原 See all EGFR (Zalutumumab Biosimilar) products
- EGFR (Zalutumumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
-
Human
-
克隆类型
- 单克隆
-
标记
- This EGFR (Zalutumumab Biosimilar) antibody is un-conjugated
- 应用范围
- ELISA, Flow Cytometry (FACS), Western Blotting (WB)
- 原理
- Anti-EGFR [2F8 (Zalutumumab, HuMax-EGFR)], Human IgG1, kappa
- 特异性
- This antibody binds domain III of the human epidermal growth factor receptor (EGFR).
- 产品特性
-
Original Species of Ab: Human
Original Format of Ab: IgG1
- 纯化方法
- Protein A affinity purified
- 免疫原
- The original monoclonal antibody was generated by immunizing HuMAb mice with alternating A431 cells and purified EGFR administration.
- 克隆位点
- 2F8
- 亚型
- IgG1 kappa
-
-
- 应用备注
- This antibody blocks the binding of EGF and TGF-α to the EGFR. At saturating concentrations, 2F8 completely blocked EGF-R signaling and inhibited the in vitro proliferation of EGF-R-overexpressing A431 cells. At much lower concentrations, associated with low receptor occupancy, 2F8 induced efficient Ab-dependent cell-mediated cytotoxicity (ADCC) in vitro. In vivo studies showed potent antitumor effects in models with A431 tumor xenografts in athymic mice. Flow cytometry was used to analyze the binding of mAb 2F8 to EGFR overexpressing A431 cells. mAb 2F8 was found to bind to membrane-associated EGF-R with an EC50 of approximately 1 μg/mL (7 nM). The ability of mAb 2F8 to block ligand-induced receptor phosphorylation was determined using immunoblotting. ELISA was used to determine whether mAb 2F8 had a functional C1q binding cite (Bleeker et al., 2004). Phase I/II clinical trials and pharmacokinetic studies in patients with advanced squamous cell carcinoma of the head and neck revealsed that 2F8/HuMax-EGFR can be safely administered in doses upto 8 mg/kg (Bastholt et al., 2007) Antibody 2F8 binds the domain III of the EGFR and locks it into a very compact and inactice conformation. Biochemical analyses showed bivalent binding of 2F8 to provide potent inhibition of EGFR signaling (Beuren et al., 2008). EGFRvIII-specific CDC was significantly enhanced when zalutumumab was combined with a Fc-engineered variant of antibody MR1-1 (Klausz et al., 2011).
- 限制
- 仅限研究用
-
- 浓度
- 1 mg/mL
- 缓冲液
- PBS with 0.02 % Proclin 300.
- 储存液
- ProClin
- 注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C,-20 °C
- 储存方法
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- 抗原
- EGFR (Zalutumumab Biosimilar)
- Abstract
- EGFR (Zalutumumab Biosimilar) 产品
- 背景
- ERBB1, ERBB, Erb-B2, HER1, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1
- UniProt
- P00533
-
You are here:
